
OBIO Stock Forecast & Price Target
OBIO Analyst Ratings
Bulls say
Orchestra BioMed Hldgs is a biomedical company with two core programs, AVIM Therapy to treat hypertension and Virtue SAB to treat atherosclerotic artery disease. These programs have significant untapped potential and key updates, such as enrollment completion by the end of 3Q26 and FDA approval of a second Breakthrough Device designation, support future market success. With a discounted cash flow analysis-based asset value of $500M and other key financial metrics, we recommend an Overweight rating, with a $10 price target reflecting a potential 12-month market value of the firm at $595M.
Bears say
Orchestra BioMed Hldgs is a biomedical company with limited human clinical data for its products and a history of operating losses. Despite partnering with larger companies, there is no assurance that the FDA will grant approval for any of its devices and commercialization partnerships may be terminated. Additionally, the company will likely need to raise debt or equity funds to complete development and commercialization, which could be difficult depending on market conditions and may be dilutive to stockholders.
This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
OBIO Analyst Forecast & Price Prediction
Start investing in OBIO
Order type
Buy in
Order amount
Est. shares
0 shares